Review Article
Anti-TNF-Alpha Therapy and Systemic Vasculitis
Table 4
Open label and randomized controlled trials performed in Behcet’s uveitis.
| References | Design/anti-TNF-α therapy | Number of patients | Main objectives | Follow-up | Main results | Side effects |
| Okada et al. [56] | Open label trial IFX | 63 | Efficacy of IFX in the first year of treatment | 12 months | Improvement in 69% Improvement somewhat in 23% Unchanged in 8% | 46% of side effects including 3 infusion reactions No serious side effects |
| Sfikakis et al. [57] | Open label trial IFX | 25 | Remission at day 28 | 28 days | 89% of complete remission | No serious side effects |
| Ohno et al. [58] | Open label trial IFX | 12 | Frequency of ocular attacks | 14 weeks | Reduction in the number of relapses for IFX (5 mg/kg and 10 mg/kg) | One case of tuberculosis (IFX 10 mg/kg) |
| Accorinti et al. [59] | Open label trial IFX | 12 | Frequency of ocular attacks | 15 months | 91% of reduction in the number of relapses | 33% of side effects including one tuberculosis and one herpetic keratitis |
| Tognon et al. [60] | Open label trial IFX | 7 | Frequency of ocular attacks | 23 months | 21 to 6 ocular attacks observed in the equivalent period of time before treatment | One infusion reaction |
| Tugal-Tutkun et al. [61] | Open label trial IFX | 13 | Absence of ocular attacks | 6 years | 31% remained attack-free 32 to 13 ocular attacks observed in the equivalent period of time before treatment | No serious side effects (7 respiratory tract infection and one infusion reaction) |
|
|